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Abstract 
AIM 
To determine the prevalence of QT prolongation in a large 
series of end stage liver disease (ESLD) patients and its 
association to clinical variables and mortality.
METHODS
The QT interval was measured and corrected for heart 
rate for each patient, with a prolonged QT cutoff defined 
as QT > 450 ms for males and QT > 470 ms for females. 
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Retrospective Study
Multiple clinical variables were evaluated including sex, 
age, serum sodium, international normalized ratio, 
creatinine, total bilirubin, beta-blocker use, Model for End-
Stage Liver Disease (MELD), MELD-Na, and etiology of 
liver disease. 
RESULTS
Among 406 ESLD patients analyzed, 207 (51.0%) had 
QT prolongation. The only clinical variable associated with 
QT prolongation was male gender (OR = 3.04, 95%CI: 
2.01-4.60, P  < 0.001). During the study period, 187 
patients (46.1%) died. QT prolongation was a significant 
independent predictor of mortality (OR = 1.69, 95%CI: 
1.03-2.77, P  = 0.039). In addition, mortality was also 
associated with viral etiology of ESLD, elevated MELD 
score and its components (P  < 0.05 for all). No significant 
reversibility in the QT interval was seen after liver 
transplantation. 
CONCLUSION
QT prolongation was commonly encountered in an ESLD 
population, especially in males, and served as a strong 
independent marker for increased mortality in ESLD 
patients. 
Key words: Cirrhosis; Electrophysiology; Arrhythmias; 
QT prolongation; Mortality; Liver transplantation
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Core tip: We performed a case-control retrospective study 
in a large cohort of patients with end stage liver disease 
(ESLD) to determine the prevalence of QT prolongation 
and its association to clinical variables and mortality. Our 
results showed a high prevalence of QT prolongation 
in ESLD patients (51%), especially in males, and QT 
prolongation was a significant independent predictor of 
mortality. Based on our findings, we recommend close 
monitoring of the QT interval in ESLD patients with 
increased attention to any modifiable causes for QT 
prolongation.
Kim SM, George B, Alcivar­Franco D, Campbell CL, Charnigo 
R, Delisle B, Hundley J, Darrat Y, Morales G, Elayi SC, Bailey 
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Available from: URL: http://www.wjgnet.com/1949­8462/full/
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INTRODUCTION
The QT interval on an electrocardiogram (ECG) is a 
measure of ventricular depolarization and repolarization. 
Prolongation of the QT interval is associated with 
ventricular arrhythmias as well as sudden cardiac death 
in both congenital and acquired conditions. Multiple 
factors are thought to be responsible for the prolongation 
of the QT interval in both congenital and acquired 
conditions, including electrolyte abnormalities, ventricular 
channelopathies, myocardial ischemia, medications, 
alcohol toxicity, and autonomic imbalance with sym­
pathetic nervous system hyperactivity[1­11]. Recent 
studies have shown that end stage liver disease (ESLD) 
is associated with several electrophysiological changes; 
specifically, an increased prevalence of QT prolongation is 
seen in this population[12­30]. While the exact mechanism 
for QT prolongation is unknown, both improvement 
in liver function and liver transplantation have been 
associated with significant shortening in the QT interval in 
studies with small sample sizes[25­31]. Likewise, previous 
studies demonstrate reduction in the QT interval for 
cirrhotic patients who receive beta­adrenergic blockade 
in both the acute and chronic settings[32­34]. Thus, this 
may be a modifiable condition and amenable to therapy. 
Although some studies suggest a prolonged QT interval 
is related to severity of liver disease, etiology of liver 
disease, and increased mortality, conflicting results exist 
regarding these important clinical questions[14,19,24­30,35,36]. 
We aimed to determine the prevalence and variables 
associated with QT prolongation in ESLD patients. 
Furthermore, we assessed whether QT prolongation was 
associated with increased mortality in these patients. 
MATERIALS AND METHODS
The research study was conducted in accordance to the 
ethical guidelines of the 1975 Declaration of Helsinki 
as reflected by approval by the institutional review 
board. After institutional review board approval was 
obtained, we performed a case­control retrospective 
study estimating the prevalence of QT prolongation in a 
cohort of cirrhotic patients with ESLD being evaluated for 
liver transplant. We then quantified the associations of 
QT prolongation with multiple clinical variables including 
etiology of liver disease, sex, age, Model for End­Stage 
Liver Disease (MELD) score, MELD­Na (MELD with 
incorporation of serum sodium) score, sodium level, 
international normalized ratio (INR), creatinine, total 
bilirubin, beta­blocker use, liver transplantation, and 
mortality. Variables were collected from the most recent 
labs collected (within 90 d of baseline ECG) as part of 
routine outpatient care. We utilized the Organ Transplant 
Tracking Record (OTTR) database and hospital records to 
identify our cohort and track their survival. 
Patients included men and women above age of 
18 with ESLD who were undergoing a liver transplant 
evaluation for any indication and had ECGs available for 
visual analysis. For patients who did not undergo a liver 
transplant, the most recent ECGs were used as baseline. 
For transplanted patients, the ECG prior to transplant was 
used as the baseline ECG while the average QT interval 
from the post­transplant ECGs was used to determine 
the effects of transplant on QT prolongation. This 
was done to eliminate artifacts due to the unstable or 
immediate post transplantation recovery period when the 
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patients’ ECGs are vulnerable to medication changes or 
electrolyte imbalances. Patients without an interpretable 
ECG, or with conduction abnormalities, recent myocardial 
infarction (within the last 30 d by history), or pacemaker 
use, were excluded from the study. 
QT determination
For all 12 lead ECGs, the QT interval based on Baz­
ett’s principle (QTc) was obtained automatically using a 
computerized ECG machine (General Electronics MAC 
5500 HD) to avoid interobserver variability. With Bazett’s 
principle, the QT interval is measured from the beginning 
of the QRS complex to the termination of the T­wave 
and divided by the square root of the R­R interval in 
seconds[37]. A QTc > 450 ms for males and a QTc > 470 
ms for females was considered abnormal or prolonged, 
as defined by European regulatory guidelines[38] and 
Goldenburg et al[39] to account for gender differences. 
Patients with QTc prolongation were subdivided into three 
categories for analytic purposes: mild (451­470 ms in 
males; 471­490 ms in females), moderate (471­490 ms 
in males; 491­510 ms in females), and severe (> 490 
ms in males; > 510 ms in females).
Statistical analysis 
Patients with (n = 207) and without QTc prolongation (n 
= 199) were compared on various clinical characteristics 
by T tests (for continuous variables and after log 
transformation for INR, creatinine, and bilirubin) and 
Fisher’s exact tests (for dichotomous variables). Logistic 
regressions with QTc prolongation as the outcome were 
performed to identify significant unadjusted and adjusted 
associations with clinical characteristics identified in the 
next sentence. The first of three multivariate models 
included beta blocker use, etiology (viral, ethanol, non­
alcohol steatohepatitis), MELD components (sodium, log 
INR, log creatinine, and log bilirubin), gender, and age 
as predictors; the second and third multivariate models 
replaced MELD components by total MELD score and total 
MELD­Na score respectively. Four logistic regressions 
with mortality as the outcome were also performed. 
The first related mortality to degree (mild, moderate, 
severe) of QTc prolongation. The second through fourth 
analyses related mortality to QTc prolongation and the 
aforementioned clinical characteristics, in parallel with the 
three multivariate models for QTc prolongation. A paired 
signed rank test was used to examine the change in QTc 
before and after surgery in a subset of patients (n = 74) 
receiving liver transplantations. Approximately 25% of 
the patients did not have routine outpatient labs within 
the 90 d of their baseline ECG. Therefore, the analyses 
involving the MELD components and MELD totals were 
performed using multiple imputation. Microsoft Excel, 
SAS, and R were used for data analysis and visualization. 
Statistical significance was declared when P < 0.05.
RESULTS
Patient characteristics
The OTTR database revealed that 729 patients were 
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evaluated for a liver transplant at the University of 
Kentucky over a recent 12­year period. Of the 729 
patients, 406 met the inclusion criteria for this study. In 
addition, approximately 25% of the patients (102 out 
of 406) did not have routine outpatient labs within the 
90 d of their baseline ECG. The effective sample size for 
comparison of QT interval pre­ and post­transplantation 
was 74. The estimated prevalence of QT prolongation 
was 51.0% (207 out of 406).
Table 1 shows that the 207 patients with QT 
prolongation (QTc by Bazett’s ≥ 450 for males and 
≥ 470 ms for females) were generally similar to the 
199 patients without QT prolongation based on clinical 
variables. However, males with QT prolongation had 
higher creatinine, MELD, and MELD­NA scores than 
males without QT prolongation. Beta­blocker use was 
more common in females without QT prolongation. 
In logistic regression analysis with QTc prolongation as 
an outcome variable, there was a significant association 
with male sex [estimated odds ratio (OR) 3.04, 95%CI: 
2.01­4.60, P < 0.001]. The association persisted in all 
three multivariate models, with adjusted OR between 
3.05 and 3.09 (P < 0.001 in all cases); there were no 
other significant predictors of QTc prolongation in these 
models. 
Of the 406 patients, 187 (46.1%) died during the 
study period. Any level (mild, moderate, or severe) 
of QTc prolongation was associated with significantly 
increased mortality (Table 2). However, the risk of 
mortality did not exhibit an increasing pattern with 
respect to the level of prolongation. 
Figure 1 shows that QTc prolongation is a significant 
predictor of mortality (OR 1.69, 95%CI: 1.03­2.77, P 
= 0.039) in a multivariate model which adjusts for the 
components of MELD and other clinical variables. This 
model also reveals significant associations with mortality 
for viral etiology, ethanol etiology, combined viral and 
ethanol etiology, INR, creatinine, and bilirubin. Figure 
2 depicts findings for an additional multivariate model 
in which MELD replaces its components, while Figure 3 
pertains to a model with MELD­Na. In all the models, 
QTc prolongation and the aforementioned etiologies 
remain significant predictors of mortality.
Effective sample size for comparison of QTc interval 
pre­ and post­transplantation was 74. Median pre­
transplant QTc was 457 with interquartile range of 435­472 
ms. Median post­transplant QTc was 450 with interquartile 
range of 429­468. Our study showed no significant 
change in the QTc interval after liver transplantation (P = 
0.24). 
DISCUSSION
Electrophysiologic cardiac abnormalities are well do­
cumented in patients with ESLD. As noted in our study, QT 
prolongation is a common finding within this population. 
Although the exact mechanism for QT prolongation in 
ESLD remains to be established, previous studies have 
suggested QT prolongation in ESLD may be multifactorial 
Kim SM et al . QT prolongation is associated with increased mortality in ESLD
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transplants[41,42]. In our study, no significant associations 
were seen between QT prolongation and these superior 
indices of ESLD, in accord with the smaller studies by 
Zurick et al[29] and Day et al[35].
Our study is unique in that we used validated 
thresholds for QT prolongation. While other studies 
used a cutoff of 440 msec, our study uses gender 
specific cutoffs as suggested by Goldenburg et al[39], to 
account for gender differences in QT prolongation that 
are typically longer for females[7,38,39,43]. Given our use 
of higher thresholds (> 450 ms for males and > 470 
for females), which allowed higher selectivity for more 
severe QT prolongation, we may have underestimated 
the prevalence of QT prolongation while overestimating 
its association with other variables. Although Adigun et 
al[30] demonstrated that a physiologic gender difference in 
the QTc interval is abolished in cirrhosis and that gender 
hormone concentrations have no effect on the QTc 
interval, our study reports a much higher prevalence of QT 
prolongation among males. When QTc prolongation was 
a dependent variable in our logistic regression models, 
both unadjusted and adjusted results showed statistically 
significant associations between QTc prolongation and male 
sex, while no other variables considered were significantly 
associated with QTc prolongation. A potential limitation to 
our study and explanation for these findings may be the 
use of gender specific thresholds and the corresponding 
assumption that gender differences in QT interval exist 
among ESLD patients. In particular, the higher cutoff 
for females may tend to understate QT prolongation 
prevalence within that gender.
Due to their utility and wide use in portal hypertension, 
the effects of acute and chronic beta­blockers on QT 
prolongation have been evaluated, with results showing a 
reduced QT interval[32­34]. In addition, partial or full reversal 
of QT prolongation following liver transplantation has 
also been noted[14,26­31]. Contrary to these findings, in our 
study, QTc prolongation was not significantly influenced 
by etiology, age, beta­blocker use, or transplantation. 
Although beta­blocker use had a trend towards lower 
and related to abnormalities in potassium channels involved 
in repolarization, high plasma concentrations of bile salts, 
and autonomic dysfunction[12­19,40]. 
In our study, the majority of patients (51.0%) 
demonstrated QT prolongation when calculated using 
Bazett’s formula. Of the 406 patients evaluated, 187 
(46.1%) died between years 2000 to 2013, confirming 
the high mortality in ESLD. An increase in mortality 
was seen at all levels of prolonged QT. Moreover, some 
etiologies and MELD components, as well as total MELD 
and MELD­Na scores, were predictive of mortality. These 
findings suggest worse outcomes in patients with viral 
hepatitis or combined viral and ethanol etiology, and 
they further validate the utility of MELD, MELD­Na, and 
its components for predicting survival in ESLD[41,42]. 
Importantly, QT prolongation predicts mortality above 
and beyond the aforementioned factors.
A number of studies have evaluated the association 
between QT prolongation and severity of ESLD as 
measured by Child­Pugh scores[14,19,24,25,28,36]. The majority 
of such studies have shown an increase in QT prolongation 
in association with higher Child­Pugh scores with the 
exception of studies done by Carey et al[27] and Adigun 
et al[30]. Due to the interobserver variability and use 
of subjective parameters in Child-Pugh classifications, 
MELD and MELD­Na scores are now widely viewed as 
superior indices for predicting mortality and allocating 
Table 1  Patient characteristics n  (%)
Variable QTc prolongation No QTc prolongation
All (n  = 207) Male (n  = 150) Female (n  = 57) All (n  = 199) Male (n  = 92) Female (n  = 107)
Beta-blocker use1 161 (77.8) 122 (81.3) 39 (68.4) 153 (77.7) 66 (71.7)  87 (82.9)3
Viral etiology   80 (38.7)   65 (43.3) 15 (26.3)   69 (34.7) 42 (45.7) 27 (25.2)
Ethanol etiology   90 (43.5)   78 (52.0) 12 (21.1)   68 (34.2) 46 (50.0) 22 (20.6)
Non-alcohol steatohepatitis etiology   47 (22.7)   28 (18.7) 19 (33.3)   57 (28.6) 13 (14.1) 44 (41.1)
Viral and ethanol etiology   35 (16.9)   32 (21.3) 3 (5.3)   24 (12.1) 17 (18.5) 7 (6.5)
Sodium2 135.6 + 6.2 135.4 + 6.4 136.3 + 5.3 136.2 + 5.6 135.4 + 5.6 136.9 + 5.6
INR2 (logarithm)    0.39 + 0.32     0.39 + 0.32     0.37 + 0.31     0.35 + 0.34     0.31 + 0.26     0.39 + 0.39
Creatinine2 (logarithm)   0.39 + 0.51     0.43 + 0.50     0.30 + 0.53     0.30 + 0.43      0.29 + 0.403     0.31 + 0.46
Bilirubin2 (logarithm)   1.19 + 1.05     1.18 + 1.07     1.20 + 0.99     1.06 + 0.96     0.90 + 0.86     1.20 + 1.03
MELD-NA2 21.0 + 9.5   21.6 + 9.5   19.5 + 9.3   19.3 + 9.1    18.6 + 7.73     19.8 + 10.2
MELD2 19.0 + 9.6   19.4 + 9.7   18.0 + 9.3   17.3 + 9.0    16.0 + 7.23     18.3 + 10.1
Age 56.1 + 9.1   56.2 + 8.8   56.0 + 9.7   56.7 + 9.0   56.3 + 9.3   57.0 + 8.7
Entries are number (percent) or mean + SD. 1Excluded for two subjects; 2Excluded for 102 subjects; 3Significantly different (P < 0.05) vs patients of same 
gender with QTc prolongation.
Table 2  Estimated odds ratios for mortality based on levels of 
QTc prolongation
OR P 95%CI
Mild QTc prolongation vs none 1.67 0.045 1.01-2.76
Moderate QTc prolongation vs none 2.11 0.013 1.17-3.81
Severe QTc prolongation vs none 1.83 0.044 1.02-3.31
Mild QTc prolongation: 451-470 ms in males and 471-490 ms in females; 
Moderate QTc prolongation: 471-490 ms in males and 491-510 ms in 
females; Severe QTc prolongation: > 490 ms in males and > 510 ms in 
females.
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prolonging drugs. As noted above, MELD variables were 
unavailable from 102 out of 406 pateints (25%) due 
to lack of outpatient labs within 90 d of their baseline 
ECG. Although MELD scores are frequently calculated 
for cirrhotics as part of their routine assessment, acute 
biochemical changes are often observed during inpatient 
hospitalizations, while labs performed outside 90 d of 
the baseline ECG may not accurately reflect the 90­d 
mortality rate assessed by MELD score in association to 
the observed ECG changes. Despite unavailable MELD 
scores on 102 patients, our analyses re-confirmed what 
is already well established in current literature that 
higher MELD scores are associated with higher mortality 
in ESLD patients. When the MELD components and 
mortality, this did not meet statistical significance. The 
lack of reversibility in the QT interval following liver 
transplantation in our study may be due to our small 
effective sample size. 
Several additional limitations need to be considered 
in our present investigation. As a retrospective study, 
our results have the potential for unintentional selection 
bias. Patients from our study were mostly Caucasian 
residing in rural areas from the state of Kentucky, 
which may not generalize geographically to the entire 
country. Our preoperative and postoperative ECGs were 
obtained during unspecified hospital or clinic visits, 
exposing our study to sampling bias related to factors 
such as electrolyte imbalance or concomitant use of QT 
Covariate Estimated odds ratio (95%CI) P -value
Beta blocker use 0.65 (0.36-1.20)     0.172
Viral etiology 2.75 (1.10-6.86)     0.030
Ethanol etiology 2.57 (1.09-6.08)     0.032
Non-alcohol steatohepatitis etiology 2.23 (0.95-5.21)     0.064
Both viral and ethanol etiology 4.93 (1.75-13.9)     0.003
Sodium (10-unit increase) 1.01 (0.64-1.58)     0.978
Log international normalized ratio (unit increase) 8.25 (2.45-27.7)     0.001
Log creatinine (unit increase) 3.57 (1.86-6.84) < 0.001
Log bilirubin (unit increase) 1.63 (1.15-2.31)     0.007
Male gender 1.07 (0.62-1.85)     0.809
Age (10-yr increase) 1.07 (0.81-1.42)     0.617
Prolongation (QTC) 1.69 (1.03-2.77)     0.039
0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00
Odds ratio
Figure 1  Association of mortality with Model for End-Stage Liver Disease components and clinical variables.
Covariate Estimated odds ratio (95%CI) P -value
Beta blocker use 0.67 (0.37-1.21)     0.187
Viral etiology 2.90 (1.19-7.08)     0.020
Ethanol etiology 2.60 (1.10-6.12)     0.029
Non-alcohol steatohepatitis etiology 2.29 (0.99-5.28)     0.053    
Both viral and ethanol etiology 5.10 (1.79-14.5)     0.003
MELD (per 10-unit increase) 4.40 (2.82-6.87) < 0.001
Male gender 1.06 (0.62-1.82)     0.834
Age (per 10-yr increase) 1.08 (0.83-1.41)     0.575    
Prolongation (QTC) 1.67 (1.02-2.73)     0.042
0.25  0.50  1.00   2.00  4.00     10.00  20.00 
Odds ratio
Figure 2  Association of mortality with total Model for End-Stage Liver Disease score and clinical variables.
Covariate Estimated odds ratio (95%CI) P -value
Beta blocker use 0.72 (0.40-1.31)     0.278
Viral etiology 2.70 (1.10-6.64)     0.030
Ethanol etiology 2.34 (1.03-5.34)     0.044
Nonalcohol steatohepatitis etiology 2.28 (1.00-5.21)     0.051
Both viral and ethanol etiology 4.28 (1.57-11.7)     0.005
MELD (per 10-unit increase) 3.60 (2.34-5.55) < 0.001
Male gender 0.98 (0.58-1.64)     0.933
Age (per 10-yr increase) 1.12 (0.86-1.47)     0.411    
Prolongalion (QTC) 1.68 (1.05-2.71)     0.032
0.25   0.50  1.00    2.00   4.00     10.00  20.00 
Odds ratio
Figure 3  Association of mortality with total Model for End-Stage Liver Disease with incorporation of serum sodium score and clinical variables.
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increased mortality, conflicting results exist regarding this important clinical 
question.
Innovations and breakthroughs
The authors aimed to determine the prevalence of QT prolongation in a large 
series of ESLD patients and its association to clinical variables and mortality. 
The QT interval was measured and corrected for heart rate (QTc) for each 
patient, with prolongation defined as QTc > 450 ms for males and QTc > 470 
ms for females. Multiple clinical variables were evaluated including sex, age, 
serum sodium, international normalized ratio, creatinine, total bilirubin, beta-
blocker use, Model for End-Stage Liver Disease (MELD), MELD-Na, and 
etiology of liver disease. Among 406 ESLD patients analyzed, 207 (51.0%) had 
QT prolongation. The only clinical variable associated with QT prolongation 
was male gender (OR = 3.04, 95%CI: 2.01-4.60, P < 0.001). During the 
study period, 187 patients (46.1%) died. QT prolongation was a significant 
independent predictor of mortality (OR = 1.69, 95%CI: 1.03-2.77, P = 0.039). 
In addition, mortality was also associated with viral etiology of ESLD, elevated 
MELD score and its components (P < 0.05 for all). No significant reversibility in 
the QTc interval was seen after liver transplantation.
Applications
QTc interval may be an independent risk factor for mortality in ESLD patients 
and thus the authors recommend close monitoring of the QT interval in ESLD 
patients and increased attention to any modifiable causes for QT prolongation 
such as electrolyte imbalances or medications.
Terminology
ESLD: End stage liver disease; MELD: Model for End-Stage Liver Disease; 
MELD-Na: Model for End-Stage Liver Disease score with serum sodium; OTTR: 
Organ Transplant Tracking Record; QTc: QT interval corrected for heart rate.
Peer-review
This is an interesting and important finding, as QT measurement is not formally 
considered in liver transplant clinics. The results of this study are interesting 
and relevant.
REFERENCES
1 Karjalainen J, Reunanen A, Ristola P, Viitasalo M. QT interval as 
a cardiac risk factor in a middle aged population. Heart 1997; 77: 
543­548 [PMID: 9227299 DOI: 10.1136/hrt.77.6.543]
2 Sawicki PT, Dähne R, Bender R, Berger M. Prolonged QT interval as 
a predictor of mortality in diabetic nephropathy. Diabetologia 1996; 
39: 77­81 [PMID: 8720606]
3 Gowda RM, Khan IA, Wilbur SL, Vasavada BC, Sacchi TJ. Torsade 
de pointes: the clinical considerations. Int J Cardiol 2004; 96: 1­6 
[PMID: 15203254 DOI: 10.1016/j.ijcard.2003.04.055]
4 Schwartz PJ, Periti M, Malliani A. The long Q­T syndrome. Am 
Heart J 1975; 89: 378­390 [PMID: 234667 DOI: 10.1016/0002­8703
(75)90089­7]
5 Surawicz B. The QT interval and cardiac arrhythmias. Annu Rev 
Med 1987; 38: 81­90 [PMID: 3555312 DOI: 10.1146/annurev.
me.38.020187.000501]
6 Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden 
death in patients with myocardial infarction. Circulation 1978; 57: 
1074­1077 [PMID: 639227 DOI: 10.1161/01.CIR.57.6.1074]
7 Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, 
Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, 
Witteman JC. Prolonged QTc interval and risk of sudden cardiac death 
in a population of older adults. J Am Coll Cardiol 2006; 47: 362­367 
[PMID: 16412861 DOI: 10.1016/j.jacc.2005.08.067]
8 Roden DM. Drug­induced prolongation of the QT interval. N Engl 
J Med 2004; 350: 1013­1022 [PMID: 14999113 DOI: 10.1056/
NEJMra032426]
9 Schooling CM, Zhao J, Zhang Y. The association of androgens 
with QT interval and heart rate in US men. Int J Cardiol 2014; 177: 
592­594 [PMID: 25205487 DOI: 10.1016/j.ijcard.2014.08.146]
10 Detta N, Frisso G, Zullo A, Sarubbi B, Cozzolino C, Romeo E, Wang 
total score were evaluated in relation to the presence 
of QT prolongation, our results did show that males 
with QT prolongation had higher creatinine, MELD, and 
MELD­NA scores than males without QT prolongation 
(Table 1). Although males with worse MELD scores (i.e., 
sicker patients) may have had a higher prevalence of 
QT prolongation, the retrospective nature of this study 
does not establish a cause and effect relationship, and 
the findings do not directly impact the main conclusion 
of our study where QT prolongation was an independent 
risk factor for mortality in ESLD.
When examining the severity of QT prolongation and 
its association with mortality, we defined mild, moderate, 
and severe levels of prolongation to categorize our 
patients. However, this categorization may not yield the 
best discriminatory power. Although the vast majority 
of heart rates in our study were within an acceptable 
range, calculation of QT intervals using Bazett’s formula 
is thought to be less accurate with particularly low or 
high heart rates[44]. Furthermore, our study relies on 
the implicit assumptions of accurate data gathering and 
correct QT interval readings from our ECG machine, 
which may be prone to systematic error; however, the 
ECG machine does eliminate interobserver variability. 
Finally, although QT prolongation has been associated 
with increased mortality secondary to ventricular 
arrhythmias, our study did not differentiate specific 
causes of death.
Our study showed that QT prolongation was com­
mon, especially for male patients, in ESLD. Although 
an association between mortality and QTc prolongation 
was evident, a greater degree of QTc prolongation did 
not clearly portend worse outcomes. Finally, while QTc 
interval may be an independent risk factor for mortality 
in ESLD patients, the exact mechanism for the increase 
in mortality remains to be established. Based on our 
findings, it is reasonable to recommend close monitoring 
of the QT interval in ESLD patients with attention to any 
modifiable causes for QT prolongation, such as electrolyte 
imbalances or medications.
COMMENTS
Background
The QT interval on an electrocardiogram (ECG) is a measure of ventricular 
depolarization and repolarization. Prolongation of the QT interval is associated 
with ventricular arrhythmias as well as sudden cardiac death in both congenital 
and acquired conditions. Multiple factors are thought to be responsible for the 
prolongation of the QT interval in both congenital and acquired conditions, 
including electrolyte abnormalities, ventricular channelopathies, myocardial 
ischemia, medications, alcohol toxicity, and autonomic imbalance with sym-
pathetic nervous system hyperactivity.
Research frontiers
Recent studies have shown that end stage liver disease (ESLD) is associated 
with several electrophysiological changes; specifically, an increased prevalence 
of QT prolongation is seen in this population. While the exact mechanism for QT 
prolongation is unknown, improvement in liver function, beta-blocker use, and 
liver transplantation have been associated with shortening in the QT interval in 
studies with small sample sizes. Although some studies suggest a prolonged 
QT interval is related to severity of liver disease, etiology of liver disease, and 
 COMMENTS
Kim SM et al . QT prolongation is associated with increased mortality in ESLD
353 April 26, 2017|Volume 9|Issue 4|WJC|www.wjgnet.com
on the corrected QT interval in patients with end­stage liver disease. 
Dig Dis Sci 2005; 50: 320­323 [PMID: 15745093 DOI: 10.1007/
s10620­005­1603­3]
28 Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship 
with etiology and severity of liver disease, mortality and liver 
transplantation. Liver Int 2003; 23: 243­248 [PMID: 12895263 DOI: 
10.1034/j.1600­0676.2003.00833.x]
29 Zurick AO, Spier BJ, Teelin TC, Lorenze KR, Alberte C, Zacks S, 
Lindstrom MJ, Pfau PR, Selzman K. Alterations in corrected QT 
interval following liver transplant in patients with end­stage liver 
disease. Clin Cardiol 2010; 33: 672­677 [PMID: 21089111 DOI: 
10.1002/clc.20801]
30 Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, 
Chalasani N. Effect of cirrhosis and liver transplantation on the gender 
difference in QT interval. Am J Cardiol 2005; 95: 691­694 [PMID: 
15721125 DOI: 10.1016/j.amjcard.2004.10.054]
31 Zamirian M, Tavassoli M, Aghasadeghi K. Corrected QT interval 
and QT dispersion in cirrhotic patients before and after liver 
transplantation. Arch Iran Med 2012; 15: 375­377 [PMID: 22642249]
32 Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non­selective 
beta­adrenergic blockade reduces prolonged frequency­adjusted Q­T 
interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40: 239­246 
[PMID: 14739094 DOI: 10.1016/j.jhep.2003.10.026]
33 Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci 
E, Caraceni P, Domenicali M, Felline P, Zoli M, Bernardi M. Effect of 
chronic beta­blockade on QT interval in patients with liver cirrhosis. 
J Hepatol 2008; 48: 415­421 [PMID: 18194821 DOI: 10.1016/
j.jhep.2007.11.012]
34 Kim YK, Hwang GS, Shin WJ, Bang JY, Cho SK, Han SM. Effect 
of propranolol on the relationship between QT interval and vagal 
modulation of heart rate variability in cirrhotic patients awaiting 
liver transplantation. Transplant Proc 2011; 43: 1654­1659 [PMID: 
21693252 DOI: 10.1016/j.transproceed.2011.02.017]
35 Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and 
sudden cardiac death in patients with alcoholic liver disease. Lancet 
1993; 341: 1423­1428 [PMID: 8099138 DOI: 10.1016/0140­6736(93)
90879­L]
36 Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval 
and its relationship to autonomic cardiovascular reflexes in patients 
with cirrhosis. J Hepatol 2001; 35: 733­738 [PMID: 11738100 DOI: 
10.1016/S0168­8278(01)00217­3]
37 Bazett HC. An analysis of the time relations of electrocardiograms. 
Heart 1920; 7: 353­367 [DOI: 10.1111/j.1542­474X.1997.tb00325.x]
38 Committee for Proprietary Medicinal Products. The assessment 
of the potential for QT interval prolongation by non­cardiovascular 
medicinal products. London: Committee for Proprietary Medicinal 
Products, 1997
39 Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it 
and what is “normal”. J Cardiovasc Electrophysiol 2006; 17: 333­336 
[PMID: 16643414 DOI: 10.1111/j.1540­8167.2006.00408.x]
40 Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electro­
physiological abnormalities in patients with cirrhosis. J Hepatol 2006; 
44: 994­1002 [PMID: 16510203 DOI: 10.1016/j.jhep.2005.10.034]
41 Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, 
Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm 
G. Evidence­based incorporation of serum sodium concentration into 
MELD. Gastroenterology 2006; 130: 1652­1660 [PMID: 16697729 
DOI: 10.1053/j.gastro.2006.02.010]
42 Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich 
J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch 
A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck­
Radosavljevic M. Child­Pugh versus MELD score in predicting 
survival in patients undergoing transjugular intrahepatic portosystemic 
shunt. Gut 2003; 52: 879­885 [PMID: 12740346 DOI: 10.1136/
gut.52.6.879]
43 Rautaharju PM, Mason JW, Akiyama T. New age- and sex-specific 
criteria for QT prolongation based on rate correction formulas that 
minimize bias at the upper normal limits. Int J Cardiol 2014; 174: 
535­540 [PMID: 24825030 DOI: 10.1016/j.ijcard.2014.04.133]
DW, Calabrò R, Salvatore F, George AL. Novel deletion mutation 
in the cardiac sodium channel inactivation gate causes long QT 
syndrome. Int J Cardiol 2013; 165: 362­365 [PMID: 22980924 DOI: 
10.1016/j.ijcard.2012.08.032]
11 Tarapués M, Cereza G, Arellano AL, Montané E, Figueras A. 
Serious QT interval prolongation with ranolazine and amiodarone. 
Int J Cardiol 2014; 172: e60­e61 [PMID: 24424337 DOI: 10.1016/
j.ijcard.2013.12.061]
12 Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. 
Dyssynchronous electrical and mechanical systole in patients with 
cirrhosis. J Hepatol 2002; 36: 513­520 [PMID: 11943423 DOI: 
10.1016/S0168­8278(02)00010­7]
13 Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and 
ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 
273: G537­G544 [PMID: 9277435]
14 Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver 
transplantation on QT interval prolongation and autonomic dysfunction 
in end­stage liver disease. Hepatology 1996; 23: 1128­1134 [PMID: 
8621144 DOI: 10.1002/hep.510230529]
15 Theocharidou E, Krag A, Bendtsen F, Møller S, Burroughs AK. 
Cardiac dysfunction in cirrhosis ­ does adrenal function play a role? 
A hypothesis. Liver Int 2012; 32: 1327­1332 [PMID: 22292920 DOI: 
10.1111/j.1478­3231.2011.02751.x]
16 Al Hamoudi W, Lee SS. Cirrhotic cardiomyopathy. Ann Hepatol 
2006; 5: 132­139 [PMID: 17060868]
17 Lazzeri C, La Villa G, Laffi G, Vecchiarino S, Gambilonghi F, 
Gentilini P, Franchi F. Autonomic regulation of heart rate and QT 
interval in nonalcoholic cirrhosis with ascites. Digestion 1997; 58: 
580­586 [PMID: 9438606 DOI: 10.1159/000201505]
18 Kempler P, Szalay F, Váradi A, Keresztes K, Kádár E, Tánczos 
E, Petrik J. Prolongation of the QTc­interval reflects the severity of 
autonomic neuropathy in primary biliary cirrhosis and in other non­
alcoholic liver diseases. Z Gastroenterol 1993; 31 Suppl 2: 96­98 
[PMID: 7483730]
19 Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, 
Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo 
G. Q­T interval prolongation in cirrhosis: prevalence, relationship 
with severity, and etiology of the disease and possible pathogenetic 
factors. Hepatology 1998; 27: 28­34 [PMID: 9425913 DOI: 10.1002/
hep.510270106]
20 Marafioti V, Benetti V, Montin U, Carbone V, Petrosino A, Tedeschi 
U, Rossi A. QTc interval prolongation and hepatic encephalopathy 
in patients candidates for liver transplantation: A valid inference? 
Int J Cardiol 2015; 188: 43­44 [PMID: 25885747 DOI: 10.1016/
j.ijcard.2015.04.026]
21 Møller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic 
cardiomyopathy. Int J Cardiol 2013; 167: 1101­1108 [PMID: 
23041091 DOI: 10.1016/j.ijcard.2012.09.089]
22 Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, 
Caraceni P, Domenicali M, Bernardi M. QT interval in patients with 
non­cirrhotic portal hypertension and in cirrhotic patients treated with 
transjugular intrahepatic porto­systemic shunt. J Hepatol 2003; 38: 
461­467 [PMID: 12663238 DOI: 10.1016/S0168­8278(03)00057­6]
23 Josefsson A, Fu M, Björnsson E, Kalaitzakis E. Prevalence of pre­
transplant electrocardiographic abnormalities and post­transplant 
cardiac events in patients with liver cirrhosis. BMC Gastroenterol 
2014; 14: 65 [PMID: 24708568 DOI: 10.1186/1471­230X­14­65]
24 Kosar F, Ates F, Sahin I, Karincaoglu M, Yildirim B. QT interval 
analysis in patients with chronic liver disease: a prospective study. 
Angiology 2007; 58: 218­224 [PMID: 17495272 DOI: 10.1177/00033
19707300368]
25 Mimidis KP, Papadopoulos V, Thomopoulos K, Tziakas D, Ritis 
K, Dalla V, Kotsiou K, Nikolopoulou V, Hatseras D, Kartalis G. 
Prolongation of the QTc interval in patients with cirrhosis. Ann 
Gastroenterol 2003; 16: 155­158
26 Finucci G, Lunardi F, Sacerdoti D, Volpin R, Bortoluzzi A, 
Bombonato G, Angeli P, Gatta A. Q­T interval prolongation in liver 
cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart 
J 1998; 39: 321­329 [PMID: 9711183 DOI: 10.1536/ihj.39.321]
27 Carey EJ, Douglas DD. Effects of orthotopic liver transplantation 
Kim SM et al . QT prolongation is associated with increased mortality in ESLD
354 April 26, 2017|Volume 9|Issue 4|WJC|www.wjgnet.com
Cardiovasc Electrophysiol 2007; 18: 77­82 [PMID: 17229304 DOI: 
10.1111/j.1540­8167.2006.00622.x]
P- Reviewer: Dourakis SP, Sinclair M    S- Editor: Ji FF    L- Editor: A 
E- Editor: Lu YJ 
44 Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani 
F, Bernardi M. QT interval correction in patients with cirrhosis. J 
Kim SM et al . QT prolongation is associated with increased mortality in ESLD
                                      © 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.f6publishing.com
